Novel Single-use Solutions for Cell & Gene Therapy Manufacturing

Register & watch

Tuesday, October 22, 2019
15:00 to 15:45 CEST (Berlin, Paris, Madrid)

As cell and gene therapies offer patients the promise of transformative treatments for challenging diseases, it’s vital to innovate and accelerate the processes that move these solutions from discovery to delivery. Join us on October 22 for our webinar, “Novel Single-use Solutions for Cell & Gene Therapy Manufacturing”, to hear more about how our solutions can help streamline your processes.

Webinar Overiew

Novel Single-use Solutions for Cell & Gene Therapy Manufacturing

Rapid advancements in cell and gene therapy development have resulted in recent product approvals bringing these transformative medicines to market. Commercializing these products have introduced a new set of challenges unique to our industry.

Single-Use products and systems have proven to enable a more flexible and cost-effective approach to traditional bio-pharma manufacturing when certain manufacturing modifications are adopted. For example, using low volume sample management systems to increase product yields and implementing ready to use sterilized solution prefilled to certain amount for addition to each step in a closed loop fashion. These new products can be used to streamline the process with consistent quality output.

The presentation will provide an overview and detail several unique challenges currently facing the commercialization of these transformative medicines including:

  • Manufacturing risks
  • Workflow constraints
  • Contamination control

Register & watch

Presented by:

Timothy Korwan

Tim is Director of New Product Development at Avantor. Tim has 20+ years of experience as an engineer and business development with VWR, PAW BioScience Products, and Biopure Corporation where he has designed single-use products, components, and systems that are used by the global drug and vaccine manufacturing industry.

Jungmin Oh

Jungmin is Manager, New Product Development at Avantor. In her current role, Jungmin leads product and process development projects with multiple biopharmaceutical industry partners, including customised product development for cell and gene therapy customers. She holds a MS and Ph.D. in chemical engineering, specialising in the optimisation of a continuous chromatography system.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.